EV / EBITDA společnosti Beam Therapeutics
Jaká je hodnota metriky EV / EBITDA společnosti Beam Therapeutics?
Hodnota metriky EV / EBITDA společnosti Beam Therapeutics Inc. je N/A
Jaká je definice metriky EV / EBITDA?
EV/EBITDA je podniková hodnota dělená EBITDA (zisk před odečtením úroků, daní, odpisů a amortizací). Měří nákladnost akcie a používá se k porovnání společností mezi sebou častěji než P/E ratio. Měří cenu, jakou investor zaplatí za pohyb hotovosti ve společnosti.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Beam Therapeutics
Čemu se věnuje společnost Beam Therapeutics?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Firmy s metrikou ev / ebitda podobnou společnosti Beam Therapeutics
- Hodnota metriky EV / EBITDA společnosti Castile Resources je N/A
- Hodnota metriky EV / EBITDA společnosti Greenhill & Co Inc je N/A
- Hodnota metriky EV / EBITDA společnosti Cool Link () je N/A
- Hodnota metriky EV / EBITDA společnosti Syntonic je N/A
- Hodnota metriky EV / EBITDA společnosti Merida Minerals Inc je N/A
- Hodnota metriky EV / EBITDA společnosti Golden Meditech je N/A
- Hodnota metriky EV / EBITDA společnosti Beam Therapeutics je N/A
- Hodnota metriky EV / EBITDA společnosti Hummingbird Resources Plc je N/A
- Hodnota metriky EV / EBITDA společnosti Tern Plc je N/A
- Hodnota metriky EV / EBITDA společnosti Magnis Resources je N/A
- Hodnota metriky EV / EBITDA společnosti Fastly Inc je N/A
- Hodnota metriky EV / EBITDA společnosti Soliton je N/A
- Hodnota metriky EV / EBITDA společnosti WeTrade je N/A